Cartesian Therapeutics Lands Up to $150 Million in Non-Dilutive Financing to Support CAR-T Commercialization Push – citybiz
- Cartesian Therapeutics Lands Up to $150 Million in Non-Dilutive Financing to Support CAR-T Commercialization Push citybiz
- Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 The Manila Times
- Cartesian secures funding to ‘accelerate’ launch; Editas sells $125M in stock Endpoints News
- Cartesian Therapeutics Inc – Enters loan and security agreement on May 22 – SEC filing marketscreener.com
- Cartesian Therapeutics (NASDAQ: RNAC) adds $150M credit line and extends cash runway Stock Titan
0
Views